Blockchain Registration Transaction Record

Soligenix Advances Novel CTCL Therapy with Visible Light Treatment

Soligenix develops HyBryte™, a visible light-activated therapy for early-stage cutaneous T-cell lymphoma (CTCL), showing significant efficacy in clinical trials while minimizing safety risks.

This development matters because CTCL represents a significant unmet medical need with limited treatment options, particularly in early stages where accurate diagnosis is notoriously difficult. Traditional phototherapies using ultraviolet light carry substantial long-term risks, including skin damage and increased cancer risk with cumulative exposure. HyBryte's visible light activation offers a potentially safer alternative that could transform treatment paradigms for this rare cancer. For patients, this could mean more effective lesion reduction with fewer side effects, improving quality of life and potentially changing disease progression. The broader implications extend to Soligenix's pipeline, which includes treatments for other inflammatory conditions and public health threats, suggesting the company's technology platform could benefit multiple patient populations facing limited therapeutic options.